# SECUADO - (3.8MG/24HR,5.7MG/24HR,7.6MG/24HR ; System)

| | | | |
|---|---|---|---|
| **Generic Name** | ASENAPINE | **Innovator** | HISAMITSU PHARM CO |
| **Dosage** | 3.8MG/24HR,5.7MG/24HR,7.6MG/24HR ; System | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | SECUADO is an atypical antipsychotic indicated for the treatment of adults with schizophrenia. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.